Ninlaro (ixazomib citrate) is a proteasome inhibitor used to treat patients with multiple myleoma, a type of cancer of the bone marrow.
The Food and Drug Administration (FDA) has specifically approved Ninlaro for use in combination with a thalidomide analog called lenalidomide (Revlimid) and dexamethasone, a corticosteroid. Ninlaro is used in multiple myleoma patients who have received at least one prior therapy.